Pharmacovigilance is defined as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problem. As new drugs flood the market after clinical trials, continuous monitoring remains vital because pre-approval studies involve small patient populations and controlled environments.
The primary goals of this discipline focus on patient care, public health, and rational drug use:
The evolution of modern pharmacovigilance is deeply rooted in pharmaceutical disasters that exposed major gaps in global drug safety. The most notable catalyst was the Thalidomide tragedy in the late 1950s and early 1960s, where a sedative prescribed for morning sickness caused severe congenital limb deformities in thousands of infants worldwide. This catastrophe forced governments to overhaul drug regulations, demanding stricter proof of safety before commercial distribution.
Another significant milestone occurred in the 1930s with the Elixir Sulfanilamide disaster, caused by the use of diethylene glycol as a solvent, leading to massive fatalities and prompting the enforcement of toxicity testing. These historical events transformed drug regulation from passive observation into active, systematic surveillance.
An Adverse Drug Reaction (ADR) differs fundamentally from a simple side effect because it involves noxious and unintended responses occurring at normal doses used for prophylaxis, diagnosis, or therapy. Understanding these reactions requires categorizing them based on predictability and mechanism.
In Nigeria, the primary agency responsible for drug safety and pharmacovigilance is the National Agency for Food and Drug Administration and Control (NAFDAC). NAFDAC coordinates nationwide safety monitoring through the Pharmacovigilance Post-Marketing Surveillance Directorate.
The cornerstone of this reporting system is the Yellow Form, a standardized tool used by healthcare workers to document suspected ADRs. Completed forms are submitted to NAFDAC physically, via email, or increasingly through digital platforms like the Med Safety mobile application. Despite these systems existing, under-reporting remains a persistent hurdle, driven by time constraints, fear of blame, and lack of awareness among clinical staff.
Pharmacovigilance extends far beyond national borders through collaborative international networks. The World Health Organization runs the WHO Programme for International Drug Monitoring, hosted by the Uppsala Monitoring Centre (UMC) in Sweden. National centers feed local data into the global database, VigiBase, allowing scientists to detect rare safety signals across continents.
At the global level, agencies like the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA) set stringent benchmarks. National bodies in low- and middle-income countries align their local guidelines with these international standards to maintain global trade safety and safeguard citizens against substandard medications.
Nurses occupy the frontline of patient care, placing them in the most strategic position to observe, identify, and report adverse drug reactions. Because nurses administer medications directly and monitor continuous patient responses, they often notice subtle physiological changes before other team members.
Clinical responsibilities in pharmacovigilance include:
Despite progress, pharmacovigilance faces significant operational hurdles, particularly in developing regions. A major obstacle is under-reporting, where busy clinicians fail to document minor or suspected side effects due to heavy workloads or fear of litigation. Additionally, the proliferation of falsified and substandard medicines in supply chains complicates safety data interpretation.
Future advancements point toward digital transformation. Artificial intelligence, electronic health records, and machine learning algorithms are beginning to scan large datasets automatically to flag safety signals faster than traditional manual reporting. Strengthening interprofessional collaboration and continuous nursing education will remain vital to overcoming these ongoing systemic barriers.